Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (4)

Publisher Name :
Date: 02-Aug-2017
No. of pages: 120
Inquire Before Buying

As a good guide for pesticide companies who are interested in commercial development of coming off-patent products, this report is CCM's fourth edition report on coming off-patent agrochemicals in the world.

This report contains profiles of 34 active ingredients (15 herbicides, 7 insecticides, 11 fungicides and 1 safener), whose patents will be expired in 2017–2022. The coming off-patent active ingredients are expected to add value to the pesticide market. Compared with developing new varieties of pesticides, to develop the pesticides whose patent have been expired will not only cost less and have lower risk, but also enjoy considerable profits. In a word, it will be a huge market with tremendous commercial value.

In this report, CCM focuses on the information of the patent products including basic information, history, synthesis route, application, physical & safety data, patent information and registration information.

Readers of this report can:


  • gain an overview of the coming off-patent products whose patents will be expired in 2017–2022;

  • know the registration situation of the hot products of agricultural giants in main agricultural countries.

Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (4)

List of Tables

Table 1.1-1 Patent information of aminopyralid in some countries/regions, as of July 2017
Table 1.1-2 Registration information of aminopyralid in China, as of July 2017
Table 1.1-3 Registration information of aminopyralid in Finland, as of July 2017
Table 1.1-4 Registration information of aminopyralid in Denmark, as of July 2017
Table 1.1-5 Registration information of aminopyralid in Canada, as of July 2017
Table 1.1-6 Registration information of aminopyralid in France, as of July 2017
Table 1.1-7 Registration information of aminopyralid in Uruguay, as of July 2017
Table 1.1-8 Registration information of aminopyralid in Australia, as of July 2017
Table 1.1-9 Registration information of aminopyralid in Switzerland, as of July 2017
Table 1.1-10 Registration information of aminopyralid in Argentina, as of July 2017
Table 1.1-11 Registration information of aminopyralid in South Africa, as of July 2017
Table 1.2-1 Patent information of flucetosulfuron in some countries/regions, as of July 2017
Table 1.2-2 Registration information of flucetosulfuron in China, as of July 2017
Table 1.3-1 Patent information of flufenpyr-ethyl in some countries/regions, as of July 2017
Table 1.4-1 Patent information of foramsulfuron in some countries/regions, as of July 2017
Table 1.4-2 Registration information of foramsulfuron in Argentina, as of July 2017
Table 1.4-3 Registration information of foramsulfuron in Denmark, as of July 2017
Table 1.4-4 Registration information of foramsulfuron in Australia, as of July 2017
Table 1.4-5 Registration information of foramsulfuron in Belgium, as of July 2017
Table 1.4-6 Registration information of foramsulfuron in Canada, as of July 2017
Table 1.4-7 Registration information of foramsulfuron in Chile, as of July 2017
Table 1.4-8 Registration information of foramsulfuron in France, as of July 2017
Table 1.4-9 Registration information of foramsulfuron in Greece, as of July 2017
Table 1.4-10 Registration information of foramsulfuron in the Netherlands, as of July 2017
Table 1.4-11 Registration information of foramsulfuron in Switzerland, as of July 2017
Table 1.4-12 Registration information of foramsulfuron in Uruguay, as of July 2017
Table 1.5-1 Patent information of metamifop in some countries/regions, as of July 2017
Table 1.5-2 Registration information of metamifop in China, as of July 2017
Table 1.5-3 Registration information of metamifop in Uruguay, as of July 2017
Table 1.6-1 Patent information of orthosulfamuron in some countries/regions, as of July 2017
Table 1.6-2 Registration information of orthosulfamuron in China, as of July 2017
Table 1.6-3 Registration information of orthosulfamuron in Brazil, as of July 2017
Table 1.7-1 Patent information of penoxsulam in some countries/regions, as of July 2017
Table 1.7-2 Registration information of penoxsulam in Argentina, as of July 2017
Table 1.7-3 Registration information of penoxsulam in Brazil, as of July 2017
Table 1.7-4 Registration information of penoxsulam in Chile, as of July 2017
Table 1.7-5 Registration information of penoxsulam in China, as of July 2017
Table 1.7-6 Registration information of penoxsulam in France, as of July 2017
Table 1.7-7 Registration information of penoxsulam in Switzerland, as of July 2017
Table 1.7-8 Registration information of penoxsulam in Uruguay, as of July 2017
Table 1.8-1 Patent information of pinoxaden in some countries/regions, as of July 2017
Table 1.8-2 Registration information of pinoxaden in Argentina, as of July 2017
Table 1.8-3 Registration information of pinoxaden in South Africa, as of July 2017
Table 1.8-4 Registration information of pinoxaden in Australia, as of July 2017
Table 1.8-5 Registration information of pinoxaden in Belgium, as of July 2017
Table 1.8-6 Registration information of pinoxaden in Canada, as of July 2017
Table 1.8-7 Registration information of pinoxaden in Chile, as of July 2017
Table 1.8-8 Registration information of pinoxaden in China, as of July 2017
Table 1.8-9 Registration information of pinoxaden in Finland, as of July 2017
Table 1.8-10 Registration information of pinoxaden in France, as of July 2017
Table 1.8-11 Registration information of pinoxaden in the Netherlands, as of July 2017
Table 1.8-12 Registration information of pinoxaden in Switzerland, as of July 2017
Table 1.8-13 Registration information of pinoxaden in Uruguay, as of July 2017
Table 1.9-1 Patent information of pyrasulfotole in some countries/regions, as of July 2017
Table 1.9-2 Registration information of pyrasulfotole in Canada, as of July 2017
Table 1.9-3 Registration information of pyrasulfotole in Australia, as of July 2017
Table 1.9-4 Registration information of pyrasulfotole in South Africa, as of July 2017
Table 1.10-1 Patent information of pyroxasulfone in some countries/regions, as of July 2017
Table 1.10-2 Registration information of pyroxasulfone in Canada, as of July 2017
Table 1.10-3 Registration information of pyroxasulfone in Australia, as of July 2017
Table 1.10-4 Registration information of pyroxasulfone in South Africa, as of July 2017
Table 1.11-1 Patent information of pyroxsulam in some countries/regions, as of July 2017
Table 1.11-2 Registration information of pyroxsulam in China, as of July 2017
Table 1.11-3 Registration information of pyroxsulam in Belgium, as of July 2017
Table 1.11-4 Registration information of pyroxsulam in Brazil, as of July 2017
Table 1.11-5 Registration information of pyroxsulam in Canada, as of July 2017
Table 1.11-6 Registration information of pyroxsulam in France, as of July 2017
Table 1.11-7 Registration information of pyroxsulam in the Netherlands, as of July 2017
Table 1.11-8 Registration information of pyroxsulam in Australia, as of July 2017
Table 1.11-9 Registration information of pyroxsulam in Switzerland, as of July 2017
Table 1.11-10 Registration information of pyroxsulam in Denmark, as of July 2017
Table 1.11-11 Registration information of pyroxsulam in Greece, as of July 2017
Table 1.11-12 Registration information of pyroxsulam in South Africa, as of July 2017
Table 1.12-1 Patent information of saflufenacil in some countries/regions, as of July 2017
Table 1.12-2 Registration information of saflufenacil in China, as of July 2017
Table 1.12-3 Registration information of saflufenacil in Brazil, as of July 2017
Table 1.12-4 Registration information of saflufenacil in Canada, as of July 2017
Table 1.12-5 Registration information of saflufenacil in Uruguay, as of July 2017
Table 1.12-6 Registration information of saflufenacil in Australia, as of July 2017
Table 1.12-7 Registration information of saflufenacil in Chile, as of July 2017
Table 1.12-8 Registration information of saflufenacil in Argentina, as of July 2017
Table 1.13-1 Patent information of tembotrione in some countries/regions, as of July 2017
Table 1.13-2 Registration information of tembotrione in Belgium, as of July 2017
Table 1.13-3 Registration information of tembotrione in South Africa, as of July 2017
Table 1.13-4 Registration information of tembotrione in Canada, as of July 2017
Table 1.13-5 Registration information of tembotrione in Chile, as of July 2017
Table 1.13-6 Registration information of tembotrione in France, as of July 2017
Table 1.13-7 Registration information of tembotrione in the Netherlands, as of July 2017
Table 1.13-8 Registration information of tembotrione in Switzerland, as of July 2017
Table 1.14-1 Patent information of thiencarbazone-methyl in some countries/regions, as of July 2017
Table 1.14-2 Registration information of thiencarbazone-methyl in Belgium, as of July 2017
Table 1.14-3 Registration information of thiencarbazone-methyl in Canada, as of July 2017
Table 1.14-4 Registration information of thiencarbazone-methyl in France, as of July 2017
Table 1.14-5 Registration information of thiencarbazone-methyl in the Netherlands, as of July 2017
Table 1.14-6 Registration information of thiencarbazone-methyl in Uruguay, as of July 2017
Table 1.14-7 Registration information of thiencarbazone-methyl in China, as of July 2017
Table 1.15-1 Patent information of topramezone in some countries/regions, as of July 2017
Table 1.15-2 Registration information of topramezone in Argentina, as of July 2017
Table 1.15-3 Registration information of topramezone in South Africa, as of July 2017
Table 1.15-4 Registration information of topramezone in Canada, as of July 2017
Table 1.15-5 Registration information of topramezone in Chile, as of July 2017
Table 1.15-6 Registration information of topramezone in China, as of July 2017
Table 1.15-7 Registration information of topramezone in Australia, as of July 2017
Table 2.1-1 Patent information of bistrifluron in some countries/regions, as of July 2017
Table 2.1-2 Registration information of bistrifluron in Australia, as of July 2017
Table 2.1-3 Registration information of bistrifluron in Argentina, as of July 2017
Table 2.2-1 Patent information of chlorantraniliprole in some countries/regions, as of July 2017
Table 2.2-2 Registration information of chlorantraniliprole in China, as of July 2017
Table 2.2-3 Registration information of chlorantraniliprole in Canada, as of July 2017
Table 2.2-4 Registration information of chlorantraniliprole in France, as of July 2017
Table 2.2-5 Registration information of chlorantraniliprole in the Netherlands, as of July 2017
Table 2.2-6 Registration information of chlorantraniliprole in Australia, as of July 2017
Table 2.2-7 Registration information of chlorantraniliprole in Switzerland, as of July 2017
Table 2.2-8 Registration information of chlorantraniliprole in South Africa, as of July 2017
Table 2.3-1 Patent information of clothianidin in some countries/regions, as of July 2017
Table 2.3-2 Registration information of clothianidin in Chile, as of July 2017
Table 2.3-3 Registration information of clothianidin in Denmark, as of July 2017
Table 2.3-4 Registration information of clothianidin in South Africa, as of July 2017
Table 2.3-5 Registration information of clothianidin in Australia, as of July 2017
Table 2.3-6 Registration information of clothianidin in Belgium, as of July 2017
Table 2.3-7 Registration information of clothianidin in Canada, as of July 2017
Table 2.3-8 Registration information of clothianidin in China, as of July 2017
Table 2.3-9 Registration information of clothianidin in Greece, as of July 2017
Table 2.3-10 Registration information of clothianidin in the Netherlands, as of July 2017
Table 2.3-11 Registration information of clothianidin in Switzerland, as of July 2017
Table 2.3-12 Registration information of clothianidin in Uruguay, as of July 2017
Table 2.3-13 Registration information of clothianidin in France, as of July 2017
Table 2.4-1 Patent information of flubendiamide in some countries/regions, as of July 2017
Table 2.4-2 Registration information of flubendiamide in Argentina, as of July 2017
Table 2.4-3 Registration information of flubendiamide in Australia, as of July 2017
Table 2.4-4 Registration information of flubendiamide in South Africa, as of July 2017
Table 2.4-5 Registration information of flubendiamide in Chile, as of July 2017
Table 2.4-6 Registration information of flubendiamide in China, as of July 2017
Table 2.4-7 Registration information of flubendiamide in Uruguay, as of July 2017
Table 2.5-1 Patent information of metofluthrin in some countries/regions, as of July 2017
Table 2.5-2 Registration information of metofluthrin in Australia, as of July 2017
Table 2.5-3 Registration information of metofluthrin in Canada, as of July 2017
Table 2.5-4 Registration information of metofluthrin in China, as of July 2017
Table 2.5-5 Registration information of metofluthrin in the Netherlands, as of July 2017
Table 2.6-1 Patent information of pyrifluquinazon in some countries/regions, as of July 2017
Table 2.7-1 Patent information of spirotetramat in some countries/regions, as of July 2017
Table 2.7-2 Registration information of spirotetramat in Argentina, as of July 2017
Table 2.7-3 Registration information of spirotetramat in Australia, as of July 2017
Table 2.7-4 Registration information of spirotetramat in Denmark, as of July 2017
Table 2.7-5 Registration information of spirotetramat in South Africa, as of July 2017
Table 2.7-6 Registration information of spirotetramat in Belgium, as of July 2017
Table 2.7-7 Registration information of spirotetramat in Canada, as of July 2017
Table 2.7-8 Registration information of spirotetramat in Chile, as of July 2017
Table 2.7-9 Registration information of spirotetramat in China, as of July 2017
Table 2.7-10 Registration information of spirotetramat in France, as of July 2017
Table 2.7-11 Registration information of spirotetramat in Greece, as of July 2017
Table 2.7-12 Registration information of spirotetramat in the Netherlands, as of July 2017
Table 2.7-13 Registration information of spirotetramat in Uruguay, as of July 2017
Table 2.7-14 Registration information of spirotetramat in Switzerland, as of July 2017
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of July 2017
Table 3.1-2 Registration information of amisulbrom in Belgium, as of July 2017
Table 3.1-3 Registration information of amisulbrom in Franch, as of July 2017
Table 3.1-4 Registration information of amisulbrom in Finland, as of July 2017
Table 3.1-5 Registration information of amisulbrom in the Netherlands, as of July 2017
Table 3.1-6 Registration information of amisulbrom in Switzerland, as of July 2017
Table 3.1-7 Registration information of amisulbrom in China, as of July 2017
Table 3.1-8 Registration information of amisulbrom in Australia, as of July 2017
Table 3.2-1 Patent information of benalaxyl-M in some countries/regions, as of July 2017
Table 3.2-2 Registration information of benalaxyl-M in Argentina, as of July 2017
Table 3.2-3 Registration information of benalaxyl-M in Belgium, as of July 2017
Table 3.2-4 Registration information of benalaxyl-M in France, as of July 2017
Table 3.2-5 Registration information of benalaxyl-M in the Netherlands, as of July 2017
Table 3.2-6 Registration information of benalaxyl-M in Switzerland, as of July 2017
Table 3.3-1 Patent information of fenpyrazamine in some countries/regions, as of July 2017
Table 3.3-2 Registration information of fenpyrazamine in Australia, as of July 2017
Table 3.3-3 Registration information of fenpyrazamine in Chile, as of July 2017
Table 3.3-4 Registration information of fenpyrazamine in Denmark, as of July 2017
Table 3.3-5 Registration information of fenpyrazamine in Belgium, as of July 2017
Table 3.3-6 Registration information of fenpyrazamine in France, as of July 2017
Table 3.3-7 Registration information of fenpyrazamine in the Netherlands, as of July 2017
Table 3.4-1 Patent information of fluopicolide in some countries/regions, as of July 2017
Table 3.4-2 Registration information of fluopicolide in Argentina, as of July 2017
Table 3.4-3 Registration information of fluopicolide in Australia, as of July 2017
Table 3.4-4 Registration information of fluopicolide in Denmark, as of July 2017
Table 3.4-5 Registration information of fluopicolide in South Africa, as of July 2017
Table 3.4-6 Registration information of fluopicolide in Belgium, as of July 2017
Table 3.4-7 Registration information of fluopicolide in Brazil, as of July 2017
Table 3.4-8 Registration information of fluopicolide in Canada, as of July 2017
Table 3.4-9 Registration information of fluopicolide in Chile, as of July 2017
Table 3.4-10 Registration information of fluopicolide in China, as of July 2017
Table 3.4-11 Registration information of fluopicolide in Finland, as of July 2017
Table 3.4-12 Registration information of fluopicolide in France, as of July 2017
Table 3.4-13 Registration information of fluopicolide in the Netherlands, as of July 2017
Table 3.4-14 Registration infromation of fluopicolide in Switzerland, as of July 2017
Table 3.4-15 Registration information of fluopicolide in Uruguay, as of July 2017
Table 3.5-1 Patent information of fluoxastrobin in some countries/regions, as of July 2017
Table 3.5-2 Registration information of fluoxastrobin in Argentina, as of July 2017
Table 3.5-3 Registration information of fluoxastrobin in Belgium, as of July 2017
Table 3.5-4 Registration information of fluoxastrobin in Canada, as of July 2017
Table 3.5-5 Registration information of fluoxastrobin in France, as of July 2017
Table 3.5-6 Registration information of fluoxastrobin in the Netherlands, as of July 2017
Table 3.5-7 Registration information of fluoxastrobin in Switzerland, as of July 2017
Table 3.5-8 Registration information of fluoxastrobin in Uruguay, as of July 2017
Table 3.5-9 Registration information of fluoxastrobin in China, as of July 2017
Table 3.6-1 Patent information of isotianil in some countries/regions, as of July 2017
Table 3.7-1 Patent information of mandipropamid in some countries/regions, as of July 2017
Table 3.7-2 Registration information of mandipropamid in Belgium, as of July 2017
Table 3.7-3 Registration information of mandipropamid in Brazil, as of July 2017
Table 3.7-4 Registration information of mandipropamid in China, as of July 2017
Table 3.7-5 Registration information of mandipropamid in Canada, as of July 2017
Table 3.7-6 Registration information of mandipropamid in France, as of July 2017
Table 3.7-7 Registration information of mandipropamid in Finland, as of July 2017
Table 3.7-8 Registration information of mandipropamid in the Nertherlands, as of July 2017
Table 3.7-9 Registration information of mandipropamid in Australia, as of July 2017
Table 3.7-10 Registration information of mandipropamid in Switzerland, as of July 2017
Table 3.7-11 Registration information of mandipropamid in Denmark, as of July 2017
Table 3.7-12 Registration information of mandipropamid in Chile, as of July 2017
Table 3.7-13 Registration information of mandipropamid in Argentina, as of July 2017
Table 3.7-14 Registration information of mandipropamid in South Africa, as of July 2017
Table 3.8-1 Patent information of metalaxyl-M in some countries/regions, as of July 2017
Table 3.8-2 Registration information of metalaxyl-M in Argentina, as of July 2017
Table 3.8-3 Registration information of metalaxyl-M in Chile, as of July 2017
Table 3.8-4 Registration information of metalaxyl-M in Denmark, as of July 2017
Table 3.8-5 Registration information of metalaxyl-M in South Africa, as of July 2017
Table 3.8-6 Registration information of metalaxyl-M in Australia, as of July 2017
Table 3.8-7 Registration information of metalaxyl-M in Belgium, as of July 2017
Table 3.8-8 Registration information of metalaxyl-M in Brazil, as of July 2017
Table 3.8-9 Registration information of metalaxyl-M in Canada, as of July 2017
Table 3.8-10 Registration information of metalaxyl-M in China, as of July 2017
Table 3.8-11 Registration information of metalaxyl-M in Finland, as of July 2017
Table 3.8-12 Registration information of metalaxyl-M in Greece, as of July 2017
Table 3.8-13 Registration information of metalaxyl-M in the Netherlands, as of July 2017
Table 3.8-14 Registration information of metalaxyl-M in Switzerland, as of July 2017
Table 3.8-15 Registration information of metalaxyl-M in Uruguay, as of July 2017
Table 3.8-16 Registration information of metalaxyl-M in France, as of July 2017
Table 3.9-1 Patent information of metrafenone in some countries/regions, as of July 2017
Table 3.9-2 Registration information of metrafenone in Australia, as of July 2017
Table 3.9-3 Registration information of metrafenone in Argentina, as of July 2017
Table 3.9-4 Registration information of metrafenone in Denmark, as of July 2017
Table 3.9-5 Registration information of metrafenone in South Africa, as of July 2017
Table 3.9-6 Registration information of metrafenone in Belgium, as of July 2017
Table 3.9-7 Registration information of metrafenone in Canada, as of July 2017
Table 3.9-8 Registration information of metrafenone in Chile, as of July 2017
Table 3.9-9 Registration information of metrafenone in Switzerland, as of July 2017
Table 3.9-10 Registration information of metrafenone in China, as of July 2017
Table 3.9-11 Registration information of metrafenone in the Netherlands, as of July 2017
Table 3.9-12 Registration information of metrafenone in France, as of July 2017
Table 3.10-1 Patent information of penflufen in some countries/regions, as of July 2017
Table 3.10-2 Registration information of penflufen in China, as of July 2017
Table 3.10-3 Registration information of penflufen in Canada, as of July 2017
Table 3.10-4 Registration information of penflufen in the Netherlands, as of July 2017
Table 3.10-5 Registration information of penflufen in Australia, as of July 2017
Table 3.11-1 Patent information of valifenalate in some countries/regions, as of July 2017
Table 3.11-2 Registration information of valifenalate in Belgium, as of July 2017
Table 3.11-3 Registration information of valifenalate in France, as of July 2017
Table 3.11-4 Registration information of valifenalate in Switzerland, as of July 2017
Table 4.1-1 Patent information of cyprosulfamide in some countries/regions, as of July 2017
Table 4.1-2 Registration information of cyprosulfamide in Belgium, as of July 2017
Table 4.1-3 Registration information of cyprosulfamide in Canada, as of July 2017
Table 4.1-4 Registration information of cyprosulfamide in Uruguay, as of July 2017
Table 4.1-5 Registration information of cyprosulfamide in Argentina, as of July 2017

List of Figures

Figure 1.1-1 Chemical structure of aminopyralid
Figure 1.2-1 Chemical structure of flucetosulfuron
Figure 1.2-2 Route for synthesizing flucetosulfuron
Figure 1.3-1 Chemical structure of flufenpyr-ethyl
Figure 1.3-2 Route for synthesizing flufenpyr-ethyl
Figure 1.4-1 Chemical structure of foramsulfuron
Figure 1.4-2 Route A for synthesizing foramsulfuron
Figure 1.4-3 Route B for synthesizing foramsulfuron
Figure 1.4-4 Route C for synthesizing foramsulfuron
Figure 1.4-5 Route D for synthesizing foramsulfuron
Figure 1.5-1 Chemical structure of metamifop
Figure 1.5-2 Route A for synthesizing metamifop
Figure 1.5-3 Route B for synthesizing metamifop
Figure 1.5-4 Route C for synthesizing metamifop
Figure 1.6-1 Chemical structure of orthosulfamuron
Figure 1.6-2 Route A for synthesizing orthosulfamuron
Figure 1.6-3 Route B for synthesizing orthosulfamuron
Figure 1.7-1 Chemical structure of penoxsulam
Figure 1.7-2 Route A for synthesizing penoxsulam
Figure 1.7-3 Route B for synthesizing penoxsulam
Figure 1.8-1 Chemical structure of pinoxaden
Figure 1.8-2 Route for synthesizing pinoxaden
Figure 1.9-1 Chemical structure of pyrasulfotole
Figure 1.10-1 Chemical structure of Pyroxasulfone
Figure 1.11-1 Chemical structure of pyroxsulam
Figure 1.12-1 Chemical structure of saflufenacil
Figure 1.13-1 Chemical structure of tembotrione
Figure 1.13-2 Route for synthesizing tembotrione
Figure 1.14-1 Chemical structure of thiencarbazone-methyl
Figure 1.15-1 Chemical structure of topramezone
Figure 1.15-2 Route for synthesizing topramezone
Figure 2.1-1 Chemical structure of bistrifluron
Figure 2.1-2 Route for synthesizing bistrifluron
Figure 2.2-1 Chemical structure of chlorantraniliprole
Figure 2.3-1 Chemical structure of clothianidin
Figure 2.3-2 Route A for synthesizing clothianidin
Figure 2.3-3 Route B for synthesizing clothianidin
Figure 2.3-4 Route C for synthesizing clothianidin
Figure 2.3-5 Route D for synthesizing clothianidin
Figure 2.4-1 Chemical structure of flubendiamide
Figure 2.5-1 Chemical structure of metofluthrin
Figure 2.5-2 Route for synthesizing metofluthrin
Figure 2.6-1 Chemical structure of pyrifluquinazon
Figure 2.7-1 Chemical structure of spirotetramat
Figure 2.7-2 Route for synthesizing spirotetramat
Figure 3.1-1 Chemical structure of amisulbrom
Figure 3.2-1 Chemical structure of benalaxyl-M
Figure 3.2-2 Route A for synthesizing benalaxyl-M
Figure 3.2-3 Route B for synthesizing benalaxyl-M
Figure 3.3-1 Chemical structure of fenpyrazamine
Figure 3.4-1 Chemical structure of fluopicolide
Figure 3.4-2 Route A for synthesizing fluopicolide
Figure 3.4-3 Route B for synthesizing fluopicolide
Figure 3.5-1 Chemical structure of fluoxastrobin
Figure 3.5-2 Route A for synthesizing fluoxastrobin
Figure 3.5-3 Route B for synthesizing fluoxastrobin
Figure 3.6-1 Chemical structure of isotianil
Figure 3.6-2 Route for synthesizing isotianil
Figure 3.7-1 Chemical structure of mandipropamid
Figure 3.8-1 Chemical structure of metalaxyl-M
Figure 3.8-2 Route A for synthesizing metalaxyl-M
Figure 3.8-3 Route B for synthesizing metalaxyl-M
Figure 3.9-1 Chemical structure of metrafenone
Figure 3.9-2 Route for synthesizing metrafenone
Figure 3.10-1 Chemical structure of penflufen
Figure 3.11-1 Chemical structure of valifenalate
Figure 4.1-1 Chemical structure of cyprosulfamide

  • Global NPK Sales Market Report 2017
    Published: 21-Sep-2017        Price: US 4000 Onwards        Pages: 108
    In this report, the global NPK market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of NPK for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast Asia ......
  • Global NPK Water-soluble Fertilizer Sales Market Report 2017
    Published: 21-Sep-2017        Price: US 4000 Onwards        Pages: 115
    In this report, the global NPK Water-soluble Fertilizer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of NPK Water-soluble Fertilizer for these regions, from 2012 to 2022 (forecast), covering - United States - China - Eur......
  • Global Diammonium Phosphate (DAP) Market Professional Survey Report 2017
    Published: 19-Sep-2017        Price: US 3500 Onwards        Pages: 126
    This report studies Diammonium Phosphate (DAP) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - PhosAgro - OCP Group - PotashCorp - Mississippi Phosphate......
  • United States Phosphatic Fertilizer Market Report 2017
    Published: 19-Sep-2017        Price: US 3800 Onwards        Pages: 108
    In this report, the United States Phosphatic Fertilizer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ra......
  • Global Gibberellin Acid (GA) Market Professional Survey Report 2017
    Published: 18-Sep-2017        Price: US 3500 Onwards        Pages: 107
    This report studies Gibberellin Acid (GA) in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Sichuan Longmang Fusheng Biotech - Jiangsu Fengyuan Bioengineering - ......
  • Global Phosphate Fertilizers Sales Market Report 2017
    Published: 18-Sep-2017        Price: US 4000 Onwards        Pages: 121
    In this report, the global Phosphate Fertilizers market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Phosphate Fertilizers for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - J......
  • Global Silica for Agrochemical Market Research Report 2017
    Published: 15-Sep-2017        Price: US 2900 Onwards        Pages: 105
    In this report, the global Silica for Agrochemical market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Silica for Agrochemical in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • Global Controlled-release Compound Fertilizer Market Research Report 2017
    Published: 15-Sep-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Controlled-release Compound Fertilizer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Controlled-release Compound Fertilizer in these regions, from 2012 to 2022 (forecast), covering - North Ameri......
  • Global Biocides Market Research Report 2017
    Published: 15-Sep-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Biocides market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Biocides in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - So......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs